Divestitures Still Possibile as Beckman Coulter Wraps Up Restructuring; Sales Force Reorganized | GenomeWeb

As Beckman Coulter nears the end of its reorganization, begun last summer, the firm is still considering divesting some "minor" product lines or other assets.

"The situation hasn't changed from the original announcement," said Paul Whitlock, a Beckman Coulter spokesperson. "We haven't actually done anything yet, but we continue to investigate those possibilities."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.